NOXOPHARM-LIMITED
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clinicians.
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages. The 1800 mg dose was deemed to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose. The high tolerance of the drug by patients with very poor lung function provides further evidence of the safety of Veyonda in patients with acute illness.
Noxopharm CEO Dr. Graham Kelly said, “The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.”
Part 2 of the NOXCOVID-1 trial now is starting to recruit a minimum of 10 and up to 15 patients with moderate-to-severe lung dysfunction. Patients will be treated for up to 14 days with an 1800 mg Veyonda dose each day.
Noxopharm is committed to pursuing its NOXCOVID program for two main reasons: Despite the advent of COVID-19 vaccines, emerging news of new mutant strains of the virus points to a likely ongoing long-term need for effective treatments for COVID-19 patients who go on to develop long-term lung damage and are at high risk of septic shock.
The current pandemic represents a small proportion of patients who die each year from septic shock. Even once the pandemic abates, the need for an effective and safe ongoing treatment for septic shock will remain.
About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda and is the major shareholder in the nononcology drug development company, Nyrada Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celebrate Excellence: 2026 SPIE Prism Awards Open for Outstanding Photonics Products9.7.2025 18:07:00 CEST | Press release
The winners will be announced 21 January at SPIE Photonics West Applications are now open for the 2026 SPIE Prism Awards. The awards, presented by SPIE, the international society for optics and photonics, recognize the most innovative products on the market, across the growing range of optics and photonics applications. The annual industry event will celebrate its 18th anniversary on 21 January, during a gala evening at SPIE Photonics West. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709679785/en/ SPIE is now welcoming submissions for its 2026 Prism Awards. In 2026, award category areas will include biophotonics instruments, cameras and imaging systems, lasers, optical materials and components, quantum tech, sensors, test and measurement, and XR tech. And now in its third year, SPIE will showcase the SPIE Catalyst Award, recognizing for-profit companies with programs that expand workplace access and opportunity, streng
SK Capital Has Entered Into Exclusive Negotiations to Acquire LISI Group’s Medical Division9.7.2025 17:45:00 CEST | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, today announced that its affiliate has entered into exclusive negotiations with LISI Group (Euronext: FII) to acquire LISI Group’s Medical division (“Lisi Medical” or the “Company”). The transaction remains subject to the approval of the competent antitrust authorities, foreign direct investment control authorities and to the information and consultation processes of the relevant employee representative bodies in accordance with applicable laws. As such, the transaction is expected to close in the second half of 2025. Lisi Medical is a leading MedTech CDMO focused on the production of high-precision metal components and assemblies serving global medical device original equipment manufacturers (“OEMs”). The Company’s products include instruments utilized in minimally invasive and robotic-assisted surgery as well as orthopedic implan
LambdaTest Enables Playwright Testing on iOS Real Devices to Enhance Mobile Test Accuracy9.7.2025 17:00:00 CEST | Press release
New capability enables QA teams to automate Playwright scripts on real iPhones and iPads for unmatched mobile testing precision LambdaTest, a GenAI-powered quality engineering platform, has announced support for Playwright testing on real iOS devices, enabling mobile web teams to run automated tests on actual iPhones and iPads using Safari. This update helps QA and engineering teams validate user experiences with far greater accuracy than simulators or emulators can offer. Testing mobile web apps on virtual environments often leads to discrepancies in real-world behavior such as missed touch interactions, inconsistent browser rendering, and undetected performance bottlenecks. LambdaTest now eliminates that uncertainty by allowing developers to execute Playwright tests on physical iOS devices. While Playwright itself does not natively support real iOS hardware, LambdaTest’s integration bridges that gap, providing seamless access to Apple’s Safari browser on real devices. Users can integ
Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 20259.7.2025 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, management and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 31, 2025. The company will host a conference call and webcast on that date to discuss the second quarter 2025 results and the 2025 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709364967/en/ Rimini Street to Report Second Quarter 2025 Financial Results on July 31, 2025 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini St
Obsidian Security Expands Go-to-Market Leadership Team to Scale SaaS Protection in the Age of AI9.7.2025 15:00:00 CEST | Press release
Leading SaaS Security Platform Strengthens Executive Bench with Five Strategic Hires as Company Scales Ahead of Growth Funding Obsidian Security, the leading SaaS security platform trusted by global enterprises including Snowflake, T-Mobile, and Pure Storage, today announced the expansion of its go-to-market leadership team with five strategic appointments. These hires position Obsidian to scale its operations as the company addresses the rapidly evolving security challenges posed by agentic AI and accelerates toward long-term growth and IPO readiness. The company has appointed Alison Tierney as VP of Go-to-Market (GTM) Strategy, Corey Elinburg as Field Chief Technology Officer, Brian McHenry as Vice President (VP) of Worldwide Solutions Engineering, Tina Lei as VP of Revenue Marketing, and Tyler Mihevc to lead Mid-Market expansion. These appointments build upon Obsidian's recent hire of Chief Product Officer (CPO) Khanh Tran, former VP of Product Management at CrowdStrike, as the comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom